Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

Table 4 Association of TRIM5 rs3824949 polymorphism with levels of plasma biomarkers in HIV/HCV coinfected patients at baseline

	CC/CG	GG	p value^a	aAMR (95 % CI)	p value^b
IP-10 or CXCL10 (pg/ml)	517.7 (573.8)	696.5 (979.4)	0.510	1.56 (0.94; 2.59)	0.082
GRO-α or CXCL1 (pg/ml)	62.6 (47.3)	80.4 (33.0)	0.064	1.40 (1.08; 1.83)	0.011
ENA-78 o CXCL5 (pg/ml)	93.4 (103.9)	114.2 (140.4)	0.391	1.26 (0.90; 1.76)	0.165
Eotaxin or CCL11 (pg/ml)	43.8 (55.5)	78.3 (67.5)	0.038	1.19 (0.89; 1.61)	0.234
MCP-1 or CCL2 (pg/ml)	28.5 (42.1)	64.3 (82.9)	0.034	1.61 (1.18; 2.19)	0.003
MCP-3 or CCL7 (pg/ml)	16.2 (17.6)	18.6 (15.7)	0.973	0.91 (0.66; 1.24)	0.543

Data are expressed in median (interquartile range)
Statistically significant differences are shown in italics
aAMR adjusted arithmetic mean ratio; 95 %CI 95 % confidence interval; IP-10 or CXCL10 IFN-γ-inducible protein 10; GRO-α or CXCL1 growth-regulated alpha protein; ENA-78 or CXCL5 epithelial-derived neutrophil-activating peptide 78; CCL11 eotaxin; MCP-1 CCL2 monocyte chemoattractant protein; CCL7 MCP-3; HCV hepatitis C virus; HIV human immunodeficiency virus
^ap values were calculated by Mann–Whitney test
^bp values were calculated by General Lineal Model (GLM) after adjusting by the most important clinical and epidemiological characteristics (see ‘‘statistical analysis’’ section)

ISSN: 1479-5876